title: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.
authors.affiliation: Liver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Gao
authors.affiliation: Liver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
authors.forename: Xiao-Ying
authors.initials: XY
authors.lastname: Wang
authors.affiliation: 1] Liver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. [2] Institute of Biomedical Sciences, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.affiliation: 1] Liver Cancer Institute and Zhongshan Hospital, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. [2] Institute of Biomedical Sciences, Shanghai Medical School, Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China.
authors.forename: Jia
authors.initials: J
authors.lastname: Fan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents